A new review looks at how endometriosis and its treatments affect bone health. The review found that, on their own, endometriosis does not seem to cause significant bone loss or increase fracture risk. However, treatments that lower estrogen, such as gonadotropin-releasing hormone (GnRH) agonists and antagonists, and some progestin-based regimens, are well known to reduce bone mineral density.
The review is a narrative review, not a new clinical trial. It summarizes existing research, which is mostly observational. The authors note that long-term data on fractures and bone quality are still lacking. They also discuss two possible ways endometriosis might affect bones: one through inflammation in the body, and another through the hormonal treatments themselves.
For patients, the key message is that while endometriosis itself may not harm bones, certain treatments can. The review suggests that doctors should assess bone health before and during treatment, especially for those at higher risk. They also mention a tool called trabecular bone score, which can help evaluate bone quality.
Overall, this review highlights the importance of monitoring bone health in women with endometriosis, particularly those using hormonal suppression. It does not provide new data, but it reinforces the need for careful management.
